Amphiphysin Antibody, IgG
Also known as: AMPHIPHYS
Use
The Amphiphysin Antibody, IgG test is used for detecting the presence of amphiphysin antibodies, which are associated with neurological conditions such as stiff-person syndrome and paraneoplastic neurological syndrome (PNS). It is useful in identifying the presence of small-cell lung cancer and breast tumors, providing valuable information for the diagnosis and management of these conditions.
Special Instructions
The test is specifically recommended for individuals with stiff-person syndrome, paraneoplastic encephalomyelitis, and sensory neuronopathy, and it may help in diagnosing occult tumors or monitoring tumor recurrence.
Limitations
The test has not been cleared or approved by the U.S. Food and Drug Administration but is performed in a CLIA-certified laboratory for clinical purposes. It is effective in identifying amphiphysin antibodies present in about 5 percent of stiff-person syndrome patients, but its utility may vary across different paraneoplastic neurological conditions.
New York Approved
Methodology
Immunoassay (Western Blot)
Biomarkers
LOINC Codes
- 94385-2
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.30 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate serum from cells ASAP or within 2 hours of collection.
Causes for Rejection
Plasma. Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |